Cardiopulmonary hemodynamics for accurate diagnosis of portopulmonary hypertension: A redefinition to consider
Mateo Porres‐Aguilar, Debabrata Mukherjee – 22 May 2014
Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma
Sui Peng, Ye Wang, Hong Peng, Dong Chen, Shunli Shen, Baogang Peng, Minhu Chen, Riccardo Lencioni, Ming Kuang – 22 May 2014 – Tumor cells express vascular endothelial growth factor (VEGF) that can activate VEGF receptors (VEGFRs) on or within tumor cells to promote growth in an angiogenesis‐independent fashion; however, this autocrine VEGF pathway has not been reported in hepatocellular carcinoma (HCC). Sorafenib, an angiogenic inhibitor, is the only drug approved for use in advanced HCC patients. Yet the treatment efficacy is diverse and the mechanism behind it remains undetermined.
Reply
Reena Mourya, Kazuhiko Bessho, Pranavkumar Shivakumar, Jorge A. Bezerra – 21 May 2014
First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: Complete remission followed by lethal sepsis
Benedikt Schaefer, Michael Steurer, Bernhard Glodny, Daniel Neureiter, Patrizia Moser, Livia Dorn, Wolfgang Vogel, Heinz Zoller – 21 May 2014
Etanercept blocks inflammatory responses orchestrated by TNF‐α to promote transplanted cell engraftment and proliferation in rat liver
Preeti Viswanathan, Sorabh Kapoor, Vinay Kumaran, Brigid Joseph, Sanjeev Gupta – 21 May 2014 – Engraftment of transplanted cells is critical for liver‐directed cell therapy, but most transplanted cells are rapidly cleared from liver sinusoids by proinflammatory cytokines/chemokines/receptors after activation of neutrophils or Kupffer cells (KCs). To define whether tumor necrosis factor alpha (TNF‐α) served roles in cell‐transplantation–induced hepatic inflammation, we used the TNF‐α antagonist, etanercept (ETN), for studies in syngeneic rat hepatocyte transplantation systems.
Dual role of B7 costimulation in obesity‐related nonalcoholic steatohepatitis and metabolic dysregulation
Antonios Chatzigeorgiou, Kyoung‐Jin Chung, Ruben Garcia‐Martin, Vasileia‐Ismini Alexaki, Anne Klotzsche‐von Ameln, Julia Phieler, David Sprott, Waldemar Kanczkowski, Theodora Tzanavari, Mohktar Bdeir, Sibylle Bergmann, Marc Cartellieri, Michael Bachmann, Polyxeni Nikolakopoulou, Andreas Androutsellis‐Theotokis, Gabriele Siegert, Stefan R. Bornstein, Michael H. Muders, Louis Boon, Katia P.
Shotgun proteomics: Identification of unique protein profiles of apoptotic bodies from biliary epithelial cells
Ana Lleo, Weici Zhang, W. Hayes McDonald, Erin H. Seeley, Patrick S.C. Leung, Ross L. Coppel, Aftab A. Ansari, David H. Adams, Simon Afford, Pietro Invernizzi, M. Eric Gershwin – 20 May 2014 – Shotgun proteomics is a powerful analytic method to characterize complex protein mixtures in combination with multidimensional liquid chromatography‐tandem mass spectrometry (LC‐MS/MS).
Hepatic expression of interleukin 8 in diagnosing biliary atresia
Rui Dong, Gong Chen, Shan Zheng, Harry Hua‐Xiang Xia – 20 May 2014
Diabetes mellitus is an independent prognostic factor for major liver‐related outcomes in patients with cirrhosis and chronic hepatitis C
Laure Elkrief, Pascale Chouinard, Noelle Bendersky, David Hajage, Béatrice Larroque, Gérard Babany, Blaise Kutala, Claire Francoz, Nathalie Boyer, Richard Moreau, François Durand, Patrick Marcellin, Pierre‐Emmanuel Rautou, Dominique Valla – 20 May 2014 – In patients with chronic hepatitis C (CHC), cirrhosis is associated with age, gender, diabetes, alcohol abuse, and coinfection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV). The effect of these factors on the outcome of cirrhosis is unknown.
Hepatocytes buried in the cirrhotic livers of patients with biliary atresia proliferate and function in the livers of urokinase‐type plasminogen activator–NOG mice
Hiroshi Suemizu, Kazuaki Nakamura, Kenji Kawai, Yuichiro Higuchi, Mureo Kasahara, Junichiro Fujimoto, Akito Tanoue, Masato Nakamura – 18 May 2014 – The pathogenesis of biliary atresia (BA), which leads to end‐stage cirrhosis in most patients, has been thought to inflame and obstruct the intrahepatic and extrahepatic bile ducts. BA is not believed to be caused by abnormalities in parenchymal hepatocytes. However, there has been no report of a detailed analysis of hepatocytes buried in the cirrhotic livers of patients with BA.